|
Analogs of peroxisome proliferator activiated receptor (PPAR) agonists, and methods of using the same
Novel PPARδ Agonists for Bone Growth
Background
Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone...
|
|
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2013-02
Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy.
Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer...
|
|
Compounds for non-lethal micropinocytosis and exosome production
Project ID: D2017-25
Background
Exosomes are vesicles in the range of 30 to 120nm, which are released from mammalian cells when multi-vesicular endosomes fuse with the plasma membrane. In recent times, exosomes have been implicated in cancer. Mounting evidence suggests that exosomes play an important role in mediating intercellular communication...
|
|
Compounds for disrupting microtubule networks and mitosis in brain cancer
Project ID: D2014-42
Background
Primary brain tumors and secondary intracranial tumors from metastatic spread of other cancers (e.g., melanoma, lung carcinoma) have been inaccessible to therapy with microtubule-targeted agents (vincristine, vinblastine, paclitaxel) because the latter do not readily cross the blood-brain barrier.
Invention...
|
|
Cancer Therapy via Simultaneous Non-apoptotic Cell Death Mechanisms
Project ID: D2018-15
Background
Most of current cancer therapy employs drugs that act through apoptotic signaling pathways. However, cancer cells often acquire mutations that can diminish apoptosis and lead to chemo-resistance when coupled with increased capacity for drug efflux and DNA repair. This results in chemotherapeutic failure especially...
|
|
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2014-33Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells....
|
